CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES

6 Months Ended

Jun. 30, 2025

Cash and Cash Equivalents [Abstract]

CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES

The following tables summarize the fair value of cash, cash equivalents and marketable securities as well as gross unrealized holding gains and losses as of June 30, 2025 and December 31, 2024:


	June 30, 2025
(in thousands)	Amortized Cost		Gross Unrealized Holding Gains		Gross Unrealized Holding Losses		Fair Value
Cash	$	7,679	$	—	$	—	$	7,679
Cash equivalents	20,736		—		—		20,736
Marketable securities	9,935		—		(3)		9,932
Total cash, cash equivalents and marketable securities	$	38,350	$	—	$	(3)	$	38,347


	December 31, 2024
(in thousands)	Amortized Cost		Gross Unrealized Holding Gains		Gross Unrealized Holding Losses		Fair Value
Cash	$	522	$	—	$	—	$	522
Cash equivalents	25,779		—		—		25,779
Marketable securities	26,767		7		—		26,774
Total cash, cash equivalents and marketable securities	$	53,068	$	7	$	—	$	53,075

The Company did not hold any securities that were in an unrealized loss position for more than 12 months as of June 30, 2025 and December 31, 2024.

There were no material realized gains or losses on available-for-sale securities during the three and six months ended June 30, 2025 and 2024.

Ovid Therapeutics Inc. 10-Q